Prestige reports positive phase 3 topline data for Avastin biosimilar
CURRENT BRIEF VERSION: Prestige Biopharma said its Phase 3 SAMSON-II trial met the primary endpoint for HD204, its proposed bevacizumab biosimilar to Avastin, in adults with advanced non-squamous non-small cell lung cancer. In the topline readout announced March 24, 2026, overall response rate at week 18 was 48.7% with HD204 versus 46.5% with Avastin, with both the risk ratio and risk difference falling inside the prespecified equivalence margins. The randomized, double-blind, multicenter study enrolled 625 patients across 91 centers in 15 countries, and Prestige said safety, progression-free survival, and overall survival were comparable between arms. HD204 has been in development for years, including earlier phase 1 pharmacokinetic work showing equivalence to US- and EU-sourced bevacizumab, and Prestige previously partnered with Intas and Accord Healthcare to commercialize the product in multiple global markets if approved. (prnewswire.com)
Why it matters: While this is a human oncology development rather than a veterinary one, it adds to the broader evidence base around biosimilar adoption, regulatory confidence, and real-world market pressure in oncology biologics. For veterinary professionals, the practical relevance is indirect but real: biosimilar competition continues to reshape expectations around biologic pricing, supply strategy, and formulary decision-making across medicine. In oncology specifically, bevacizumab biosimilars have become a major part of the market, with recent market analyses showing high biosimilar share and deeper price discounts in the US. And beyond bevacizumab, the broader biosimilar pipeline keeps moving: recent regulatory updates include FDA approval of Teva’s denosumab biosimilar Ponlimsi and FDA/EMA acceptance of Teva’s omalizumab biosimilar filings, both supported by analytical and clinical packages showing similar efficacy, safety, and immunogenicity to their reference products. Together, those developments reinforce how regulators continue to rely on the totality-of-evidence model across biologic classes, even as reimbursement design, education gaps, and payer dynamics still influence uptake. (centerforbiosimilars.com)
What to watch: Watch for full SAMSON-II data presentation, regulatory filing timing in the US and Europe, and whether Prestige and its commercial partners move quickly toward launch planning. More broadly, continued approvals and filing acceptances in other biosimilar categories, including denosumab and omalizumab, will help show how durable that regulatory and commercial momentum really is. (prnewswire.com)